NovImmune leverages its expertise in immunology by capitalizing on its in-depth familiarity with its mAb generating technologies (CAT and Medarex), its innovative and broad mAbs pipeline and a solid intellectual property position.

In order to maximize the value of our expertise and portfolio that already delivered 2 mAbs to clinical development, partnering activities with leading pharmaceutical companies are key to our business strategy. For the time being NovImmune is focusing on the initial, research intensive, part of the value chain which has already delivered two antibodies into the clinical development. NovImmune has been investing resources also in new technologies and in down-stream processes. 

NovImmune would like to retain the option of keeping selected orphan drug indications for in-house development beyond Phase II clinical trials, especially for well-defined, smaller indications.

• Selectively partner mAbs that address high medical need, in large patient populations with companies interested in biologicals, preferably after clinical proof-of-concept in phase II

• Provide biopharmaceutical partners strategic access to our dedicated, immunology-focused, efficient and comprehensive R&D engine

For partnering inquiries contact:

Luca Bolliger, PhD

Director, Business Development
Tel    +41 22 593 51 15
Fax   +41 22 839 71 46
Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it